![]() |
|||
![]() |
![]() |
||
|
Marc Goldstein, Ph.D., is a Product Platform Manager in Beckman Coulter’s Automation and Information Systems Business Center. He is responsible for managing the business of platform hardware and software product, including the Biomek® Laboratory Automation Workstations, SAMI® Software EX and the new BioRAPTR FRD™ and PicoRAPTR™ low-volume microfluidic workstations. Marc’s academic training focused on the enzymatic breakdown of wood, specifically the initiation of the cellulolytic process by the binding of a cellulase component to the crystalline cellulose matrix—a project that gave him extensive experience with techniques spannng the range of traditional microbiology, biochemistry, biophysics and molecular biology. He obtained a Ph.D. in Microbiology from U.C. Davis and his work resulted in many papers and a patent for technology that is in use today. After a brief post-doc appointment at U.C. Davis, Marc left academia to take up an Application Specialist position supporting automated DNA sequencing. Having gained a strong understanding of modern automated genetic analysis processes, Marc joined Beckman Coulter in early 1998 as a Project Manager, supporting the proper configuration, installation and startup of automated systems such as CORE™ Systems and Assay Workstations. Since then, he has held positions of increasing responsibility including heading the North American Project Management team, gaining experience with all the common assay technologies that support the drug discovery process as well as modern genetic analysis. Mary Xueyun Guan, RAC Mary has extensive knowledge from previous positions at Beckman Coulter in which she supported the implementation process of clinical diagnostics analyzers. Additionally, Mary obtained her United States Regulatory Affairs Certification (RAC, US) in 2006. Keith Roby Currently, Keith is responsible for applications on the Biomek®, RAPTR™ and PARADIGM™ platforms.
* All trademarks are the property of their respective owners. Where applicable, the PCR process is covered by patents owned by Roche Molecular Systems, Inc., and F. Hoffmann-LaRoche, Ltd. For Research Use Only; not for use in diagnostic procedures. For comments or questions about T3 Update, please contact the T3 Editor.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||